Neisseria meningitidis

TRUMENBA safety information

Scroll for Important Safety Information and Indication

IMPORTANT SAFETY INFORMATION
  • Severe allergic reaction after a previous dose of Trumenba is a contraindication
  • Individuals with altered immunocompetence may have reduced immune responses to Trumenba
  • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at the injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%)
  • Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Safety and effectiveness have not been established in pregnant women

INDICATION
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
  • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed

Please see full Prescribing Information.

TRUMENBA in your practice

A MenB vaccine series may be administered to individuals aged 16 through 23 years.2

ACIP recommendations for meningitis B vaccine series

The science behind TRUMENBA

Only TRUMENBA targets both fHBP subfamilies, A and B.1,3

Subfamilies A and B of fHBP

TRUMENBA clinical studies

TRUMENBA demonstrated cross-coverage by targeting MenB strains expressing both subfamilies. A and B, of fHBP.1

Coadministration with Trumenba® (Meningococcal
Group B Vaccine)
*Advisory Committee on Immunization Practices.

REFERENCES

  • Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2017.
  • MacNeil JR, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(41):1171-1176.
  • McNeil LK, Murphy E, Zhao XJ, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine. 2009;27(25-26):3417-3421.